RecruitingPhase 1

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

China58 participantsStarted 2026-04-14

Plain-language summary

This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.

Who can participate

Age range

18 Years – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Subjects aged 18 to 55 years (inclusive), regardless of gender;
. Body mass index (BMI) between 19 and 28 kg/m² (inclusive), with body weight ≥ 50.0 kg and \< 90.0 kg for men, and ≥ 45.0 kg and \< 90.0 kg for women;
. No abnormalities of clinical significance are found upon comprehensive physical examination and laboratory tests, or only minor abnormalities that are deemed by the investigator not to affect the subject's eligibility for enrollment;
. No clinically significant abnormalities on the 12-lead ECG;
. The subject must understand the study procedures and methods, voluntarily agree to participate, and provide written informed consent.

Exclusion criteria

. Subjects with suspected hypersensitivity to the investigational drug or any excipient;
. The subject has a history of syncope;
. Exclusion due to blood pressure: Systolic Blood Pressure (SBP) \>140 mmHg or \<90 mmHg; OR Diastolic Blood Pressure (DBP) \>90 mmHg or \<60 mmHg, as determined by the investigator to be clinically significant;
. History of gastric or intestinal surgery that, in the investigator's judgment, may affect drug absorption;

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Peak concentration (Cmax).

Timeframe: From Day 1 to Day 17.

Area under the plasma concentration - time curve from Time 0 to the last quantifiable time point (AUC0-t).

Timeframe: From Day 1 to Day 17.

Area under the plasma concentration - time curve from Time 0 to infinity (AUC0-∞).

Timeframe: From Day 1 to Day 17.

Trial details

NCT IDNCT07479641

SponsorShandong Suncadia Medicine Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-07

Contact for this trial

Wenzheng Xiong

+86-0518-82342973 wenzheng.xiong.wx10@hengrui.com

View on ClinicalTrials.gov More Cardiomyopathy trials

Who can participate

Age range

18 Years – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Subjects aged 18 to 55 years (inclusive), regardless of gender;
. Body mass index (BMI) between 19 and 28 kg/m² (inclusive), with body weight ≥ 50.0 kg and \< 90.0 kg for men, and ≥ 45.0 kg and \< 90.0 kg for women;
. No abnormalities of clinical significance are found upon comprehensive physical examination and laboratory tests, or only minor abnormalities that are deemed by the investigator not to affect the subject's eligibility for enrollment;
. No clinically significant abnormalities on the 12-lead ECG;
. The subject must understand the study procedures and methods, voluntarily agree to participate, and provide written informed consent.

Exclusion criteria

. Subjects with suspected hypersensitivity to the investigational drug or any excipient;
. The subject has a history of syncope;
. Exclusion due to blood pressure: Systolic Blood Pressure (SBP) \>140 mmHg or \<90 mmHg; OR Diastolic Blood Pressure (DBP) \>90 mmHg or \<60 mmHg, as determined by the investigator to be clinically significant;
. History of gastric or intestinal surgery that, in the investigator's judgment, may affect drug absorption;

What they're measuring

Peak concentration (Cmax).

Timeframe: From Day 1 to Day 17.

Area under the plasma concentration - time curve from Time 0 to the last quantifiable time point (AUC0-t).

Timeframe: From Day 1 to Day 17.

Area under the plasma concentration - time curve from Time 0 to infinity (AUC0-∞).

Timeframe: From Day 1 to Day 17.